Douglas Pharmaceuticals secures US licensing deal to treat high grade cervical dysplasia
Ketamine ER by Douglas Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval
Douglas Pharma’s Chief Scientific Officer talks about a new drug for treatment resistant depression
Formation of Clinical Advisory Board for Lead Program R-107
AUCKLAND, New Zealand, Jan. 26, 2023 /PRNewswire/ -- Douglas Pharmaceuticals, a New Zealand Pharmaceutical company focused on specialty generic and repurposed drug development, today announced the formation of a clinical advisory board to support its lead program R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD).
Douglas Pharmaceuticals tackles treatment-resistant depression
New Zealand’s largest medical R&D facility opens in West Auckland
Clinicians China licenced to HTDK Pharmaceuticals
AUCKLAND, New Zealand, Dec. 16, 2021 /PRNewswire/ -- Douglas Pharmaceuticals Ltd (Douglas), a privately held New Zealand-headquartered pharmaceutical company, today announced positive top-line data from its multinational, randomized, placebo-controlled, double-blind Phase 2 study of R-107 designed to investigate the efficacy and safety of R-107 (ketamine 30, 60, 120 or 180 mg) versus placebo for TRD. This study was conducted in New Zealand, Australia, Singapore, and Taiwan from 2019 to 2021, with 231 TRD patients enriched, and 168 patients randomized.
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021. Details are as follows: